$INSY Vanguard Group Inc grew its stake in shares of Insys Therapeutics by 4.7% during the third quarter. Vanguard Group Inc now owns 2,661,324 shares of the specialty pharmaceutical company’s stock valued at $26,825,000 after acquiring an additional 119,776 shares in the last quarter. Vanguard Group Inc. grew its stake in Insys Therapeutics by 4.7% in the third quarter. Vanguard Group Inc. now owns 2,661,324 shares of the specialty pharmaceutical company’s stock worth $26,825,000 after purchasing an additional 119,776 shares in the last quarter. MetLife Investment Advisors LLC acquired a new position in Insys Therapeutics in the third quarter worth about $223,000. BlueMountain Capital Management LLC grew its stake in Insys Therapeutics by 533.6% in the third quarter. BlueMountain Capital Management LLC now owns 28,145 shares of the specialty pharmaceutical company’s stock worth $284,000 after purchasing an additional 23,703 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in Insys Therapeutics in the third quarter worth about $113,000. Hedge funds and other institutional investors own 17.22% of the company’s stock.